# Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

> **NCT01089751** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 322 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** trospium chloride
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01089751
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 322 (ACTUAL)
- **Last updated:** 2013-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01089751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01089751, "Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01089751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*